Background Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in patients with cirrhosis represent a significant therapeutic challenge as they are associated with poor outcomes due to high rates of treatment failure, and frequently induce liver decompensation. Aims To evaluate treatment failure and in-hospital mortality in two cohorts of patients with cirrhosis and with CRKP infections treated with antibiotic regimens including or excluding Ceftazidime-avibactam.
Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections in Patients With Liver Cirrhosis / Feldman, Shani; Russo, Alessandro; Ceccarelli, Giancarlo; Borrazzo, Cristian; Madge, Chiara; Venditti, Mario; Merli, Manuela. - In: JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY. - ISSN 0973-6883. - 120:11(2022), pp. 1994-2002. [10.1016/j.jceh.2022.04.016]
Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections in Patients With Liver Cirrhosis
Giancarlo Ceccarelli;Mario Venditti;Manuela Merli
Conceptualization
2022
Abstract
Background Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in patients with cirrhosis represent a significant therapeutic challenge as they are associated with poor outcomes due to high rates of treatment failure, and frequently induce liver decompensation. Aims To evaluate treatment failure and in-hospital mortality in two cohorts of patients with cirrhosis and with CRKP infections treated with antibiotic regimens including or excluding Ceftazidime-avibactam.| File | Dimensione | Formato | |
|---|---|---|---|
|
Ceftazidime-Avibactam.pdf
accesso aperto
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
453.8 kB
Formato
Adobe PDF
|
453.8 kB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
